rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

BioHarvest Sciences Inc.

BHST · Nasdaq

Health CareBiotechnologyNot moving yet

BHST stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 50 weeks. It is 42.4% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 50
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
17 (-2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders17-2 on the quarter
New · exited2 · 3
Reported value$3.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Alyeska Investment Group, L.P.reduced · filed 14 Aug 2026581,441$1.7M-175,623−23.2%
Evercore Wealth Management, LLCadded · filed 14 Aug 2026216,343$619K+76,873+55.1%
True North Advisors, LLCadded · filed 22 Jul 2026187,318$536K+19,305+11.5%
Magnus Financial Group LLCadded · filed 9 Jul 202690,000$257K+35,000+63.6%
SUSQUEHANNA INTERNATIONAL GROUP, LLPadded · filed 14 Aug 202663,658$180K+47,264+288.3%
Silverberg Bernstein Capital Management LLCadded · filed 7 Jul 202657,723$163K+31,624+121.2%
KING LUTHER CAPITAL MANAGEMENT CORPunchanged · filed 10 Aug 202640,000$114K00.0%
TD Waterhouse Canada Inc.unchanged · filed 27 Jul 202623,827$66K00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 202620,652$58K+5,899+40.0%
XTX Topco Ltdreduced · filed 14 Aug 202613,232$37K-16,417−55.4%
31 Dec 2024 – 30 Jun 2026
61218Dec 24Jun 25Sep 25Mar 26Jun 26

Everyone who traded it

Nobody on record has traded it.

Same industry

MRNA ModernaLeading+167%
IOVA Iovance BiotherapeuticsLeading+141%
ABCL AbCellera BiologicsLeading+57%
ENTX Entera BioLeading+52%
HALO Halozyme TherapeuticsLeading+48%
XERS Xeris Biopharma HoldingsLeading+47%
XNCR XencorLeading+41%
HELP Helus PharmaLeading+39%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202559.3%
Operating profit marginFY 2025 · to 31 Dec 2025-16.2%
Free cash flow marginFY 2025 · to 31 Dec 2025-27.8%
Return on capital employedFY 2025 · to 31 Dec 2025-13.9%
Debt to equityFY 2025 · to 31 Dec 20250.01×
Research spendFY 2025 · to 31 Dec 202515.4%
Revenue growthFY 2025 · to 31 Dec 202537.0%
Share count trendFY 2025 · to 31 Dec 202530.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$23.0M
Free cash flowFY 2025 · to 31 Dec 2025−$9.6M

Analyst forecasts

No analyst forecasts yet.